UTI Healthcare Reg IDCW-P

The UTI Healthcare Fund is an equity-oriented sectoral mutual fund scheme. It invests primarily in companies operating in the healthcare sector, including pharmaceuticals and healthcare services. The scheme seeks to participate in the growth potential of businesses operating across diagnostic centres, hospitals, biotechnology , pharmaceuticals, and other healthcare-related services.

The scheme is categorised under “Very High Risk”, as it is a sectoral equity fund with concentrated exposure to healthcare-related companies.

In the IDCW Payout Option, any available distributable surplus may be distributed to investors as cash. The Net Asset Value (NAV) is reduced by the amount distributed on the ex-dividend date. IDCW is subject to the availability of surplus and trustee discretion and is not guaranteed.

Pros

Healthcare services play a fundamental role in sustaining modern society by promoting, maintaining, and restoring human well-being. Here are some main benefits of this scheme:

1. Diversified Healthcare Portfolio
   The scheme invests across multiple healthcare-related industries, which include laboratories, hospitals, biotechnology firms, and specialty healthcare businesses. However, the portfolio remains concentrated within a single sector (healthcare), meaning diversification benefits are limited to sub-sectors only. This structure may enable investors to achieve capital growth across multiple healthcare segments.

2. Participation in Expanding Healthcare Segments
   Specialty healthcare areas such as oncology, cardiology, nephrology, and fertility treatment have observed increasing demand in recent years. Companies operating in these segments may experience growth, subject to regulatory approvals, pricing pressure, and demand cycles. The scheme enables investors to access businesses in these distinct segments.

3. Access to Emerging Healthcare Opportunities
   India’s healthcare industry is evolving with growth in telemedicine, diagnostics, and multi-specialty hospitals. The scheme allows investors to participate in these developing areas through a diversified portfolio of listed healthcare-sector equities.

4. Multi-Cap Healthcare Exposure
   The scheme may invest across small-cap, mid-cap, and large-cap stocks. Participation across market capitalisations offers a combination of stability and growth potential within the healthcare sector. However, portfolio data indicates meaningful exposure across mid-cap and small-cap segments, which may increase volatility.

Cons

The growth of healthcare companies is highly sensitive to regulatory, operational, and economic factors. The scheme has the following limitations:

1. VeryHigh RiskProfile
   The scheme is categorised under the ‘Very High Risk’ segment because of heavy exposure to equity markets. During market corrections or economic downturns, healthcare stocks may also experience sharp volatility, negatively impacting portfolio value.

2. Regulatory and Policy Sensitivity
   The healthcare and pharmaceutical industries operate within heavily regulated environments. Changes in medicine pricing policies, export regulations, compliance standards, or approval processes may affect profitability. Since the scheme has significant exposure to pharmaceutical companies such as Sun Pharmaceuticals and Lupin, regulatory changes may materially affect NAV performance.

3. Supply Chain and Operational Risks
   Healthcare companies rely on supply chains for raw materials, logistics, and medical instruments. Disruptions in supply chains or manufacturing delays may increase costs and affect profitability, which can impact fund returns.

4. Sector Concentration Risk
   The portfolio is highly concentrated in the healthcare sector, with top sector exposure exceeding ~95% as per available portfolio data. This high concentration increases vulnerability to sector-specific downturns compared to diversified equity funds.